Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Gene Therapy

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/gt.2014.127PMID 25652179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stable isotopes in the diagnosis and treatment of inherited hyperammonemia

  2014cited by this paper
• Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.

  2014cited by this paper
• Minimal Ureagenesis is Necessary for Survival in the Murine Model of Hyperargininemia Treated by AAV-based Gene Therapy

  2014cited by this paper
• AAV-based Gene Therapy Prevents Neuropathology and Results in Normal Cognitive Development in the Hyperargininemic Mouse

  2013cited by this paper
• Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice.

  2013cited by this paper
• Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.

  2013cited by this paper
• AAV-based Neonatal Gene Therapy for Hemophilia A: Long-Term Correction and Avoidance of Immune Responses in Mice

  2012cited by this paper
• Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy.

  2012cited by this paper
• Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?

  2011cited by this paper
• Measuring in vivo ureagenesis with stable isotopes.

  2010cited by this paper
• RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy

  2010cited by this paper
• Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.

  2009cited by this paper
• AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.

  2009cited by this paper
• N-carbamylglutamate Markedly Enhances Ureagenesis in N-acetylglutamate Deficiency and Propionic Acidemia as Measured by Isotopic Incorporation and Blood Biomarkers

  2008cited by this paper
• Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.

  2006cited by this paper
• Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate.

  2004cited by this paper
• Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema.

  2003cited by this paper
• Mouse Model for Human Arginase Deficiency

  2002cited by this paper
• Proceedings of a consensus conference for the management of patients with urea cycle disorders.

  2001cited by this paper
• In vivo measurement of ureagenesis with stable isotopes

  1998cited by this paper
• Argininemia: A Treatable Genetic Cause of Progressive Spastic Diplegia Simulating Cerebral Palsy: Case Reports and Literature Review

  1997cited by this paper
• o-Phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromatography of polypeptide hydrolysates and physiological fluids.

  1983cited by this paper
• Insulin decreases and hydrocortisone increases the synthesis of glutamine synthetase in cultured 3T3-L1 adipocytes.

  1983cited by this paper
• Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion.

  1982cited by this paper

• Gene therapy for urea cycle defects: An update from historical perspectives to future prospects

  2023cites this paper
• Gene Therapy for Inherited Metabolic Diseases

  2020cites this paper
• The Pharmabiotic Approach to Treat Hyperammonemia

  2018cites this paper
• Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice.

  2018cites this paper
• The Main Neurological Dysfunctions in Hyperargininemia-Literature Review

  2018cites this paper
• AS PRINCIPAIS DISFUNÇÕES NEUROLÓGICAS EM HIPERARGININEMIA – REVISÃO DE LITERATURA

  2017cites this paper
• Delivering efficient liver-directed AAV-mediated gene therapy

  2017cites this paper
• A gene therapy approach for Argininosuccinic aciduria

  2017cites this paper
• Investigating Nucleotide Deficiency-Based Genomic Instability and CRISPR/Cas9-mediated Genomic Addition for the Therapeutic Applications of Human Induced Pluripotent Stem Cells

  2016cites this paper
• Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to Arginase-deficient Induced Pluripotent Stem Cells

  2016cites this paper
• Strategies to Rescue the Consequences of Inducible Arginase-1 Deficiency in Mice

  2015cites this paper